PARTNERSHIP AGREEMENT No. 012174-1NOHL-00Partnership Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
This partnership agreement (the “Partnership Agreement”) is made and entered into as of February 1, 2013 (the “Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its principal place of business at 1bis Allée du Sauze, 69160 Tassin la Demi-Lune, France (“GenSight”), and Genethon, a non-profit organization organized under the laws of France, with its principal place of business at 1bis, rue de l’Internationale, 91002 Evry Cedex, France (SIRET: 40218752000018) (“Genethon”), (each of GenSight and Genethon a “Party” individually and collectively the “Parties”).
RESEARCH COLLABORATION AGREEMENTResearch Collaboration Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances) • Basel-Stadt
This Research Collaboration Agreement (the “Agreement”) having an Effective Date of March 1st, 2014, is made between the Friedrich Miescher Institute for Biomedical Research (“FMI”) located at Maulbeerstrasse 66, 4058 Basel, Switzerland, (Principal Investigator Dr. Botond Roska), and GenSight Biologics, located at 89 Rue du Fbg Saint Antoine, 75011 Paris, France (“GenSight”), (Principal Investigator Dr. Didier Pruneau), under the following terms and conditions.
LICENSE AGREEMENT N° 05064A10License Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
This License Agreement (the “Agreement”) is made as of its last date of signature by all signatories (the “Effective Date”) by and between:
ContractLicense Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
ContractSpecific Research Cooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
ContractConsortium Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
LICENSE AGREEMENTLicense Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances) • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into effective as of February 23, 2014 (the “Effective Date”) between GENSIGHT BIOLOGICS, S.A., a French corporation with offices at 89, rue du Faubourg St Antoine 75011 Paris (“GenSight”), and AVALANCHE BIOTECHNOLOGIES, INC., a Delaware corporation with offices at 665 Third Street, Suite 280, San Francisco, CA 94107 (“Avalanche”).
ContractSpecific Research Cooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
ADDENDUM 1 No. 012174-1NOHL-01 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OOPartnership Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
This Project Addendum 1 (the “Project Addendum 1”) is made and entered into as of 2 April 2013 (the “Project Addendum 1 Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its principal place of business at 1bis Allée du Sauze, 69160 Tassin la Demi-Lune, France (“GenSight”), and Genethon, a non-profit organization organized under the laws of France, with its principal place of business at 1bis, rue de l’Internationale, 91002 Evry Cedex, France (SIRET: 40218752000018) (“Genethon”), (each of GenSight and Genethon a “Party” individually and collectively the “Parties”).
ADDENDUM 1.1 No. 012174-1NOHL-01.1 TO THE PARTNERSHIP AGREEMENT No. 012174-1NOHL-OOPartnership Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
This Project Addendum 1.1 (the “Project Addendum 1.1”) is made and entered into as of 1 January 2014 (the “Project Addendum 1.1 Effective Date”), by and between GenSight Biologics SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its principal place of business at 74 rue du Faubourg Saint Antoine 75012 Paris, France (“GenSight”), and Genethon, a non-profit organization organized under the laws of France, with its principal place of business at 1bis, rue de l’Internationale, 91002 Evry Cedex, France (SIRET: 40218752000018) (“Genethon”), (each of GenSight and Genethon a “Party” individually and collectively the “Parties”).
QUALITY AGREEMENT No. 014180-1NOHL-00Quality Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
This quality agreement (the “Quality Agreement”) is made and entered into as of 10th June 2014, by and between GENETHON, a non-profit organization organized under the laws of France (SIRET: 40218752000018), with its principal place of business at 1bis, rue de l’Internationale, 91002 Evry Cedex, France (“GENETHON”), and GENSIGHT-BIOLOGICS SA, a corporation organized under the laws of France, registered with the Lyon Trade and Company Registry under number B 751 164 757 (SIRET: 75116475700013), with its principal place of business at 74 rue du Faubourg Saint Antoine, 75012 Paris, France (“GENSIGHT”), (each of GENSIGHT and GENETHON a “Party” individually and collectively the “Parties”).
ContractCooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
REFUNDABLE ADVANCE BENEFICIARY AGREEMENT (FINANCIAL AID AGREEMENT) Funding for Business Cluster Development ProjectRefundable Advance Beneficiary Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
A French public limited company (“Société Anonyme”) with share capital of €759,916,144, registered in the Créteil Trade and Companies Register under number 320 252 489, whose head office is at 27-31 Avenue du Général Leclerc, 94710 Maisons-Alfort,
1st AMENDMENT TO THE COOPERATION AGREEMENTCooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05
ContractMaster Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
2nd AMENDMENT TO THE COOPERATION AGREEMENTCooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
Pierre and Marie Curie University (Paris 6), a French public, scientific, cultural and professional establishment located at 4 Place Jussieu, 75252 Paris Cedex 05
ContractCooperation Agreement • July 7th, 2015 • Gensight Biologics • Biological products, (no disgnostic substances)
[**] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission.
